MindBio enters 25th participant into triple blind, double dummy, active placebo controlled microdosing trial in depressed patients

Hi

Join me as I discuss MindBio's landmark take-home microdosing clinical trial in patients with Major Depressive Disorder as we enter our 25th participant into this randomized, triple blind, double dummy, active placebo controlled trial.

Click to Watch

We thank you for your support and interest in our scientific work.

Click on the link to view the video here

Stay Well!

JUSTIN HANKA

Chief Executive Officer & Co-Founder

MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)

Follow CEO Justin Hanka on LinkedIn:

https://www.linkedin.com/in/justinhanka/

Follow MindBio on LinkedIn: https://www.linkedin.com/company/mindbio-therapeutics/?viewAsMember=true